

Biography

Professor Brigette Buig-Yue Ma 馬碧如

Bachelor of Medicine, Bachelor of Surgery, MBBS
(Monash University)
Doctor of Medicine (CUHK)
Fellow of the Royal Australasian College of
Physicians (FRACP)
Fellow Hong Kong College of Physicians (FHKCP)
Fellow Hong Kong Academy of Medicine (FHKAM,
Medicine)



Brigette Ma is currently Professor and Honorary Consultant at the Department of Clinical Oncology, The Chinese University of Hong Kong (CUHK), Medical Director (Oncology) of the CUHK Phase I Clinical Trial Centre. Professor Ma received her undergraduate degree with Honours at Monash University, Australia, and was awarded Fellow of the Royal Australasian College of Physicians, Fellow of Hong Kong College of Physicians, and Doctor of Medicine (CUHK). She underwent training in Medical Oncology at the Peter MacCallum Cancer Institute, Melbourne, and was Clinical Research Fellow (Developmental Therapeutics) at the Princess Margaret Hospital, Toronto, Canada.

Professor Ma is dedicated to the development of innovative early phase clinical trials, novel immunotherapeutic combinations and in advancing precision medicine and multimodal therapy for cancers of the head and neck and colorectal cancer. She has published over 220 peer-reviewed papers, including book chapters and high impact journals such as Journal of Clinical Oncology, Lancet Oncology, New England Journal of Medicine, Nature Medicine/ Nature Communications. As Study Chair of international co-operative group studies (NRG oncology, US National Cancer Institute Cancer Therapy Evaluation Program, US-NCI CTEP), sponsored trials and investigator-initiated clinical trials, she has played a leading role in clinical research in nasopharyngeal cancer, colorectal cancer and Early Developmental therapeutics. She is also co-/Principal Investigator in several government grants including Collaborative Research Fund in precision medicine in Colorectal Cancer. She received the 7th Kobayashi Foundation Award for her contribution to research in Nasopharyngeal Cancer in 2023.

Professor Ma has a long history of service to several influential international oncology societies including the European Society of Medical Oncology (ESMO, > 40,000 members), American Society of Clinical Oncology (ASCO, > 50,000 members), American Association of Cancer Research (AACR, > 50,000 members) and Chinese Society of Clinical Oncology (> 30,000 members). Notably, she is council member of ESMO which consists of a group of around 17 scientists who have made significant contributions to cancer research, who advise the ESMO Executive Board on strategic development. She has served as Scientific Co-Chair for several important events including ESMO

Asia 2023 Congress, ESMO Asia Early Drug Development Advanced Course and the ESMO Targeted Anticancer Therapy. Professor Ma has contributed to the development of clinical guidelines such as the first ESMO practice guideline for metastatic colorectal cancer, and the ASCO-CSCO guideline for locally advanced nasopharyngeal cancer. Recently, she has been invited to be member of the ESMO Early Detection and Prevention (EDEPT) Task Force. Over the years, she has served as Keynote Speaker, Track Chairs and Oral Discussant at numerous international research and educational events including ASCO annual conference, ESMO preceptorship programs for Head and Neck, GI cancer and immunotherapy, as well as Advanced Courses in Drug Development and in the Development of Antibody Conjugates in GI cancers. She has served in many international research committees such as the US-NCI Head and Neck Cancer Steering Committee - Clinical Trials Planning Group on Nasopharyngeal Cancer, Women in Cancer Research (WICR) of the AACR, ASCO International Affairs Committee and the NRG Head & Neck Committee.

Amongst her other roles, she is Associate Editor of Oral Oncology and is member of the Editorial Boards of the Journal of Clinical Oncology, ESMO Open, ESMO GI Oncology, Clinical Colorectal Cancer and Therapeutic Advances in Medical Oncology. She is Chair of the CUHK-New Territories East Cluster Ethics Committee for phase 1 studies.